The short answer
The evidence checked does not establish that flaxseed increases bleeding with zanubrutinib or requires a specific separation interval. Review concentrated products with the team, particularly if you have low platelets.
What this answer covers
Linum usitatissimum whole seed, meal and oil with oral zanubrutinib. Accessible human interaction-related trials used flaxseed oil, not every plant preparation.
- Supplement or preparation
- Linum usitatissimum
- Medication ingredient
- zanubrutinib
Check the prescribed treatment
This review concerns oral zanubrutinib in BRUKINSA capsules or tablets for selected blood cancers. Follow the exact product’s instructions and blood-count monitoring plan. The medicine can cause bleeding, but a drug warning alone does not prove that every supplement adds to that risk.
Some platelet tests changed in a small study
A study of eleven healthy men compared large daily amounts of flaxseed oil with sunflower oil. Some collagen-triggered platelet responses decreased with flaxseed oil. This was a laboratory endpoint in a small oil study, not proof of clinical bleeding with zanubrutinib.
Another trial found no clotting-test change
A seven-week study in adults with metabolic syndrome found no significant difference in clotting measures between flaxseed and sunflower oils. Neither study tested zanubrutinib. Whole flaxseed, meal, fiber-rich preparations and extracted oil differ, so results should not be interchanged.
Do not invent a bleeding-prevention schedule
Show the team the actual flax product and purpose. They can review your platelet count and other medicines. Moving doses apart has not been shown to prevent a bleeding interaction; follow the cancer-drug monitoring plan and promptly report unusual bleeding.
Evidence and practical considerations
Side effects & toxicity
Small oil studies show mixed laboratory findings, not a confirmed zanubrutinib bleeding interaction or whole-seed timing requirement.
- Exact scope
- Linum usitatissimum whole seed, meal and oil with oral zanubrutinib. Accessible human interaction-related trials used flaxseed oil, not every plant preparation. with RxNorm 2262435 IN zanubrutinib. Exact current oral product: BRUKINSA oral zanubrutinib capsules and tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- Oil-only human proxy studies, no target-pair clinical bleeding study or verified whole-seed absorption effect. No validated interval.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Bleeding and cytopenia warnings; CYP3A inhibitor/inducer effects. Named citrus guidance separately sourced to capsule information.
How this applies: RxNorm 2262435 IN zanubrutinib. Exact current oral product: BRUKINSA oral zanubrutinib capsules and tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 11 healthy young men.
Some collagen-induced platelet aggregation responses decreased with flaxseed oil.
How this applies: Exact preparation/population/endpoints only; applicability to zanubrutinib independently assessed.
Abstract-only small proxy study; not clinical bleeding, whole flaxseed or zanubrutinib co-use.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 60 adults with metabolic syndrome randomized; 52 completed.
No significant coagulation-score/PT/PTT difference between groups.
How this applies: Exact preparation/population/endpoints only; applicability to zanubrutinib independently assessed.
Original body; not a major-bleeding trial or whole-seed product and not cancer treatment.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
zanubrutinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 81aa75e3f1f45e99
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.